Diagnostic and prognostic value of 99mTc-Tektrotyd
scintigraphy and 18F-FDG PET/CT in a single-center
cohort of neuroendocrine tumors

Saponjski, Jovica; Macut, Djuro; Petrović, Nikola; Ognjanović, Sanja; Popović, Bojana; Bukumirić, Zoran; Šaranović, Dragana Šobić

doi:10.5114/aoms/130996

Cited by 5 publications

(3 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results demonstrate a very good diagnostic utility of 99m Tc-EDDA/HYNIC-TOC scintigraphy, with high sensitivity, specificity, accuracy, positive and negative predictive values, in concordance with outcomes obtained by other authors. Our sensitivity of 90.5% is higher than the ones obtained by other authors [ 23 , 24 , 25 , 26 ], but lower to the ones obtained in 68 Ga-studies.…”

Section: Discussioncontrasting

confidence: 81%

“…Several authors analyzed the efficacy of this technique as well. Saponjski et al [ 23 ] studied the diagnostic and prognostic value of 99m Tc-EDDA/HYNIC-TOC SRS in comparison to 18 F-FDG PET/CT in all types of NETs and concluded that 18 F-FDG PET/CT had a higher sensitivity than SRS (92% vs. 83.6%), probably correlated to the higher number of patients with high tumoral-grade NETs (27 NET G2 tumors and 15 NET G3 tumors). The other values obtained for 99m Tc-EDDA/HYNIC-TOC SRS were a specificity of 82.6% and an accuracy of 83.3%.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The New Radiolabeled Peptide 99mTcEDDA/HYNIC-TOC: Is It a Feasible Choice for Diagnosing Gastroenteropancreatic NETs?

Gherghe

Lazăr

Stanciu

et al. 2022

Cancers

View full text Add to dashboard Cite

(1) Background: The aim of our study is to reveal the advantages and limitations of the use of 99mTcEDDA/HYNIC-TOC (Tektrotyd®, Polatom) in the diagnosis of gastroenteropancreatic neuroendocrine tumors and to compare our results with the values obtained for 111In-pentetreotide and 68Ga-DOTA-peptides, routinely used in medical practice. (2) Methods: This retrospective monocentric study included 173 patients with gastroenteropancreatic neuroendocrine tumors who underwent 99mTcEDDA/HYNIC-TOC scans as part of their clinical management. The examination protocol included a whole-body scan acquired 2 h after the radiotracer’s administration, with the SPECT/CT performed 4 h post-injection. Physiological and abnormal uptake were established by two experienced physicians and, based on the obtained results, sensitivity, specificity, accuracy, positive predictive value and negative predictive value were calculated. (3) Results: Our method presented a sensitivity of 90.5%, a specificity of 71.9%, and an accuracy of 84.3%, with a positive predictive value of 86.7% and a negative predictive value of 78.8%. (4) Conclusions: 99mTc-EDDA/HYNIC-TOC, a receptor-based radiopharmaceutical, could represent a competitor for 68Ga-labeled peptides in the diagnosis and management of patients with gastroenteropancreatic neuroendocrine tumors. Our results show a lower sensitivity (90.5%) than 68Ga-DOTA-peptides, but with great specificity, accuracy, positive, and negative predictive values.

show abstract

Section: Discussioncontrasting

confidence: 81%

Section: Discussionmentioning

confidence: 99%

The New Radiolabeled Peptide 99mTcEDDA/HYNIC-TOC: Is It a Feasible Choice for Diagnosing Gastroenteropancreatic NETs?

Gherghe

Lazăr

Stanciu

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…An activity distribution based on Tektrotyd studies was investigated as this may be an area of clinical practice where the accurate application of PVC could be important. The semi-quantitative Krenning score which assesses the uptake in lesions relative to the uptake in the liver and in the spleen [28] has been shown to correlate with outcome [29]. In general, lesions are assessed visually, however there is interest in reviewing these studies with quantitative SPECT [18].…”

Section: Discussionmentioning

confidence: 99%

Towards accurate partial volume correction in 99mTc oncology SPECT: perturbation for case-specific resolution estimation

et al. 2022

View full text Add to dashboard Cite

Background Currently, there is no consensus on the optimal partial volume correction (PVC) algorithm for oncology imaging. Several existing PVC methods require knowledge of the reconstructed resolution, usually as the point spread function (PSF)—often assumed to be spatially invariant. However, this is not the case for SPECT imaging. This work aimed to assess the accuracy of SPECT quantification when PVC is applied using a case-specific PSF. Methods Simulations of SPECT $$^{99{\mathrm{m}}}$$ 99 m Tc imaging were performed for a range of activity distributions, including those replicating typical clinical oncology studies. Gaussian PSFs in reconstructed images were estimated using perturbation with a small point source. Estimates of the PSF were made in situations which could be encountered in a patient study, including; different positions in the field of view, different lesion shapes, sizes and contrasts, noise-free and noisy data. Ground truth images were convolved with the perturbation-estimated PSF, and with a PSF reflecting the resolution at the centre of the field of view. Both were compared with reconstructed images and the root-mean-square error calculated to assess the accuracy of the estimated PSF. PVC was applied using Single Target Correction, incorporating the perturbation-estimated PSF. Corrected regional mean values were assessed for quantitative accuracy. Results Perturbation-estimated PSF values demonstrated dependence on the position in the Field of View and the number of OSEM iterations. A lower root mean squared error was observed when convolution of the ground truth image was performed with the perturbation-estimated PSF, compared with convolution using a different PSF. Regional mean values following PVC using the perturbation-estimated PSF were more accurate than uncorrected data, or data corrected with PVC using an unsuitable PSF. This was the case for both simple and anthropomorphic phantoms. For the simple phantom, regional mean values were within 0.7% of the ground truth values. Accuracy improved after 5 or more OSEM iterations (10 subsets). For the anthropomorphic phantoms, post-correction regional mean values were within 1.6% of the ground truth values for noise-free uniform lesions. Conclusion Perturbation using a simulated point source could potentially improve quantitative SPECT accuracy via the application of PVC, provided that sufficient reconstruction iterations are used.

show abstract

Diagnostic Value of Radiolabelled Somatostatin Analogues for Neuroendocrine Tumour Diagnosis: The Benefits and Drawbacks of [64Cu]Cu-DOTA-TOC

Vahidfar

Farzanehfar

Abbasi

et al. 2022

Cancers

View full text Add to dashboard Cite

Neuroendocrine tumours (NETs) arise from secondary epithelial cell lines in the gastrointestinal or respiratory system organs. The rate of development of these tumours varies from an indolent to an aggressive course, typically being initially asymptomatic. The identification of these tumours is difficult, particularly because the primary tumour is often small and undetectable by conventional anatomical imaging. Consequently, diagnosis of NETs is complicated and has been a significant challenge until recently. In the last 30 years, the advent of novel nuclear medicine diagnostic procedures has led to a substantial increase in NET detection. Great varieties of exclusive single photon emission computed tomography (SPECT) and positron emission tomography (PET) radiopharmaceuticals for detecting NETs are being applied successfully in clinical settings, including [111In]In-pentetreotide, [99mTc]Tc-HYNIC-TOC/TATE, [68Ga]Ga-DOTA-TATE, and [64Cu]Cu-DOTA-TOC/TATE. Among these tracers for functional imaging, PET radiopharmaceuticals are clearly and substantially superior to planar or SPECT imaging radiopharmaceuticals. The main advantages include higher resolution, better sensitivity and increased lesion-to-background uptake. An advantage of diagnosis with a radiopharmaceutical is the capacity of theranostics to provide concomitant diagnosis and treatment with particulate radionuclides, such as beta and alpha emitters including Lutetium-177 (177Lu) and Actinium-225 (225Ac). Due to these unique challenges involved with diagnosing NETs, various PET tracers have been developed. This review compares the clinical characteristics of radiolabelled somatostatin analogues for NET diagnosis, focusing on the most recently FDA-approved [64Cu]Cu-DOTA-TATE as a state-of-the art NET-PET/CT radiopharmaceutical.

show abstract

Diagnostic and prognostic value of 99mTc-Tektrotyd scintigraphy and 18F-FDG PET/CT in a single-center cohort of neuroendocrine tumors

Cited by 5 publications

References 30 publications

The New Radiolabeled Peptide 99mTcEDDA/HYNIC-TOC: Is It a Feasible Choice for Diagnosing Gastroenteropancreatic NETs?

The New Radiolabeled Peptide 99mTcEDDA/HYNIC-TOC: Is It a Feasible Choice for Diagnosing Gastroenteropancreatic NETs?

Towards accurate partial volume correction in 99mTc oncology SPECT: perturbation for case-specific resolution estimation

Diagnostic Value of Radiolabelled Somatostatin Analogues for Neuroendocrine Tumour Diagnosis: The Benefits and Drawbacks of [64Cu]Cu-DOTA-TOC

Contact Info

Product

Resources

About